ACE2 and COVID-19: CRP is among the first biomarker to be altered in the inflammation process and thus is a potentially useful predictor of disease outcome in COVID-19 [3]. Elevated liver enzymes indicate hepatic damage; specifically, aspartate aminotransferase (AST) has been proposed to be elevated in subjects with severe COVID-19. The tropism of the virus towards angiotensin-converting enzyme-2 (ACE-2) receptors, which are abundant in the liver and bile duct cells, is supposed to be the pivotal factor in liver damage [4].